Latest news

latest news

We’ll show you what’s new with us here, offer you interesting media outlets that relate to our work, and you can find our press releases here.


Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund I

Sep 27, 2022

Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund.

CasInvent Pharma Raises €1.3 Million from KHAN-I and i&i Biotech Fund

Sep 13, 2022

CasInvent Pharma, an early-stage drug discovery company developing small-molecule compounds with anticancer properties, has raised a follow-up investment round of €1.3 million provided by KHAN-I and i&i Bio. With this funding, CasInvent Pharma will be strengthening its portfolio of casein kinase inhibitors and progressing its lead compound to the development candidate status.

Roche Latvia Innovations Day

Notes from a trip to “The most startup friendly country in the world”

Jun 13, 2022

At the end of April, Karel Kubias (one of the partners of i&i Biotech Fund) and Jiří Moos (CEO of i&i Prague) attended an event in Riga, Latvia, called Roche Latvia Innovations Day. Here you can read their blog where they describe their impressions from the event and, more importantly, provide further evidence that the Baltic States can serve as inspiration for the Czech Republic. 

Jaromír Zahrádka On SEznam zprávy agenda podcast

Apr 13, 2022

Check out the new episode of the Agenda podcast on Seznam Zprávy. Jaromír Zahrádka, CEO of i&i Bio, talked about our investments this year, investing in Life Sciences and how to find a champion. The video is in Czech language.

Agenda SZ Jaromir.jpg
Sampling Human logo

i&i Biotech fund Invests $1.5 Million in Sampling Human to Support the Development of Engineered Cells for Single Cell Analysis

Apr 12, 2022

This year's third i&i Bio investment goes to Sampling Human, an early stage, Life Sciences technology company that has developed a diagnostic platform that harnesses genetically engineered cells to analyze other cells in their environment.

i&i Bio's investment of $2 million goes to Dracen Pharmaceuticals, company developing cancer-fighting drugs

Mar 7, 2022

i&i Bio has announced investment of USD 2 million in Dracen Pharmaceuticals. This company is completing the first phase of clinical testing of DRP-104 (sirpiglenastat), which has the potential to significantly help the treatment of cancer. 

Dracen Pharmaceuticals logo
Celeris Therapeutics logo

i&i Biotech Fund invests €1 million in Celeris Therapeutics, company using AI to develop drugs 

Feb 24, 2022

i&i Bio has announced an investment of EUR 1 million in CelerisTx, an early-stage drug discovery company using artificial intelligence to predict biomolecular interactions and generate new chemical entities. CelerisTx exploits its proprietary platform to develop new drugs in oncology and neurology. 

Jaromír Zahrádka On the Life Science Get2Gether podcast

Dec 12, 2021

In mid-December, Christian Soschner invited our CEO Jaromír Zahrádka to his podcast, which he regularly broadcasts on Life Science Get2Gether (LS G2G).

Jaromír Zahrádka - sklo, starší
i&i Bio opening press release

i&i Bio, the newly established investment fund

Sep 23, 2021

It is our pleasure to announce the start of operations of i&i Biotech Fund (i&i Bio) in September 2021.